Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30662745 | 0.89 | KDM4E (0.43) | CSNK2A1GSK3AGSK3BCYP1A2CYP3A4 | |
| SCHEMBL301294 | 0.89 | KDM4E (0.43) | CSNK2A1GSK3AGSK3BCYP1A2CYP3A4 | |
| SCHEMBL28029215 | 0.77 | GSK3A (0.36) | GSK3AGSK3BKDM4ETSHRMEN1 | |
| SCHEMBL28298219 | 0.77 | GSK3A (0.36) | GSK3AGSK3BKDM4ETSHRMEN1 | |
| SCHEMBL4048492 | 0.67 | MAP2K3 (0.42) | CSNK2A1CSNK2A2CSNK2BTBK1MAP2K3 | |
| SCHEMBL28028866 | 0.67 | MAPT (0.40) | GSK3AGSK3BCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL28298212 | 0.67 | MAPT (0.40) | GSK3AGSK3BCYP2C9CYP2C19CYP1A2 | |
| SCHEMBL4376889 | 0.65 | ALDH1A1 (0.45) | KDM4EUSP2MAPTALDH1A1HPGD | |
| SCHEMBL8474128 | 0.62 | CRBN (0.43) | KDM4EUSP2CDK5CDK5R1LMNA | |
| SCHEMBL746783 | 0.61 | CRBN (0.66) | GSK3AGSK3BKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | claimed |
| CN-102574849-A | Herbicidal compounds | SYNGENTA LTD | 2012-07-11 | — | — | CN | claimed |
| EP-2078018-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2012-03-14 | — | — | EP | claimed |
| CN-109846884-A | With TOR kinase inhibitor for treating cancer | 西格诺药品有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-105039520-A | Identification of gene expression profile as a predictive biomarker for lkb1 status | SIGNAL PHARM LLC | 2015-11-11 | — | — | CN | disclosed |
| CN-101679432-B | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2015-04-22 | — | — | CN | disclosed |
| CN-104271139-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-104271138-A | Treatment of cancer with tor kinase inhibitors | SIGNAL PHARM LLC | 2015-01-07 | — | — | CN | disclosed |
| CN-103857804-A | Identification of gene expression profiles as predictive biomarkers for LKB1 status | SIGNAL PHARM LLC | 2014-06-11 | — | — | CN | disclosed |
| CN-102821767-A | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARM LLC | 2012-12-12 | — | — | CN | disclosed |
| CN-102574849-A | Herbicidal compounds | SYNGENTA LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-101679432-A | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC | 2010-03-24 | — | — | CN | disclosed |